However, given the high co-morbidity of FXS and ASD43, the use of [18F]FPEB to examine differences in mGluR5 binding potential between these disorder groups could significantly contribute to our understanding of the differences in underlying pathophysiology of the disorders; towards development of mechanism-based novel therapeutics in neurodevelopmental disorders. This evidence concerns the gene GRM5 and fragile X syndrome.